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AML is an aggressive hematological malignancy with highest incidence in the older adults. The adverse
features of AML in the elderly, and the frailties and comorbidities frequently present in them, make their
management a particularly difﬁcult therapeutic challenge. In this context, it is important to assess
carefully patient- as well as disease-associated prognostic features with validated tools. The ﬁttest pa-
tients should be considered for curative therapy, such as bone marrow transplantation, whereas low
intensity options may be more appropriate for frail patients. Here we review how to assess patients with
elderly AML and the treatments options available for them.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
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Acute myeloid leukemia (AML) is a rare disease afﬂicting an-
nually 3–4 persons per 100,000 individuals. With a median age at
diagnosis of 67 years, this disease is far more common in the el-
derly [1]. In this age group, AML has a particularly dismal outcome
with less than 5% of the patients being alive 5 years after the di-
agnosis, as compared to 40% in the young [2,3]. Considering that
individuals aged 65 in the Western world are expected to survive
approximately another 20 years, and even those aged 80 three
additional years [4], AML has a devastating impact on the survival
of this age group.Ltd. This is an open access article u
os).The reasons for the poor outcomes in the older adults are both
patient- and disease-related. Advanced age is often accompanied
by frailty and comorbidities, which have an important impact on
the tolerance these patients have to intensive treatment mod-
alities [5]. In addition, the lower rates of complete remission (CR)
in the elderly (40–50% vs 60–70% in the young) [3] and the short
duration seen in those who are eligible for treatment [5], point
towards a different disease biology in this age group. From a
clinical viewpoint, it is far more frequent for elderly patients to
have received previous cytotoxic treatment or radiotherapy or to
have antecedent hematologic diseases, such as myelodysplastic
(MDS) or myeloproliferative neoplasms [5]. In addition to these
clinical features, the cytogenetic proﬁle of elderly patients with
AML also differs from that of younger patients, presenting a
greater incidence of multiple chromosomal abnormalities [6]. The
introduction of new potent sequencing technologies has shednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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physiology, and further reinforced the observation that AML in the
elderly is biologically distinct. Thus, mutation screening has
identiﬁed mutations in genes coding for epigenetic regulators,
such as TET2, DMNT3A, IDH1/2, ASXL1 and EZH2, kinases and cell
cycle regulators, such as TP53, NPM1 and FLT3 and transcription
factors, such as RUNX1 and CEBPA [7], and showed that the cy-
togenetic and mutational proﬁle of AML in the older adults pa-
tients is signiﬁcantly different from that of younger patients [8].
The methylation patterns seen in them resemble more closely
those seen in MDS [9]. These unique features of AML in the elderly
population urge a fresh approach to these patients.2. Geriatric assessment
Older adults frequently have an advanced biological age. This
not a constant feature and a number of them keep ﬁt and healthy
until late in their lives. Nevertheless, the opportunity to develop
several diseases, as well as to acquire a low functional reserve,
increases with chronological age and any experienced malignant
hematologist recognizes that some elderly AML patients may be
unable to withstand intensive chemotherapy and allogeneic he-
mopoietic cell transplantation. An excruciating clinical problem is
how to predict with conﬁdence such a situation when confronting
an apparently ﬁt/unﬁt individual patient. In this situation, a
comprehensive geriatric assessment (CGA) is the appropriate an-
swer and the National Comprehensive Cancer Network has issued
speciﬁc guidelines to help the physician in the care of older adults
with cancer [10]. However, CGA is somehow complex and not al-
ways readily available. Some screening tools (e.g. VES13 or G8)
have been developed to decide which patients deserve a CGA in
order to optimize resources [11,12]. Despite the fact that they
predict survival in hematological patients (eg. G8 score up to 14
score points seems a bad prognostic factor), their sensitivity and
speciﬁcity as compared to the gold standard (i.e. CGA) is not op-
timal [13,14] and a simpliﬁed geriatric assessment approach is
much needed and now actively pursued (see the next section). Our
suggestion for this purpose, based on the approach of Klepin et al.
[15,16], is shown in Table 1 and requires that the clinical team
becomes familiar with some additional clinical tools beyond per-
formance status and comorbidity scores [17,18], such us the Short
Physical Performance Battery [19], or the more straightforwardTable 1
Assessment at diagnosis of an older adult AML patient. Based on Klepin et al. [15], mod
Clinical context Ancillary data Therap
A. Centers with optimal geriatric facilities
All patients Perform CGA on time To be d
geriatr
B. Centers with basic or inadequate geriatric facilities
ECOG 0–2 Adequate physical performance
Lack of major comorbidity Lack of cognitive dysfunction ICT/HC
Preserved ADLs Low risk for HCT (NRM)
ECOG 0–2 Inadequate physical performance
Lack of major comorbidity Cognitive dysfunction (even mild) Vulner
underPreserved ADLs High risk for HCT (NRM)
ECOG 3–4 not linked to AML
Major comorbidity (CCI or HCT-CI)




Doubtful cases Consider consultation with a geriatrician
and social worker
Case-b
ADLs: Activities of daily life. AML: Acute myeloid leukemia. CGA: Comprehensive geriatr
transplantation. ICT: Intensive chemotherapy. NRM: Non-relapse mortality. Standard AM
risk stratiﬁcation and predicted HCT-linked NRM. Alternative AML therapy: low-dose cyGait Speed [20,21], as well as the Modiﬁed Mini-Mental Score [22]
or the Short Portable Mental Status Questionnaire [23].3. Prognosis
The management of AML in the elderly patient presents a sig-
niﬁcant challenge for hematologists. Careful evaluation of both
patient and disease is required in each individual case to make
optimal management decisions, and maximize the beneﬁt to the
patient. Apart from the extremely old patients, chronological age
per se is particularly unreliable in identifying patients who will not
tolerate intensive regimens.
As stated in the introduction, AML in the older adult shows some
biological differences with AML in the young. As far as prognostic
factors are concerned (see Table 2), the vast majority are the same,
but their relative proportion is different. The data from MRC/LRF,
based on more than two thousand patients included in clinical trials
in UK, showed that age, performance status, white blood cell count,
cytogenetics, and type of AML (de novo vs. secondary) are the most
relevant prognostic factors [24]. Recent analysis of population-de-
rived data from Sweden [25] included outcomes from over 3000
adult AML patients, of which 26% had secondary AML. Analysis of
prognostic factors found that secondary AML signiﬁcantly impacted
survival in younger patients but, in older patients, it did not emerge
as an independent poor prognostic factor, suggesting that second-
ary AML lacks the prognostic impact in this population previously
attributed by the MRC/LRF [24].
Flow cytometry has attained a central role in the diagnosis of
AML and recent data have shown that the degree of phenotypic
maturity determined by this technique can also deliver important
prognostic information in the elders [26]. These phenotypes can
predict both CR rates and survival, suggesting that they reﬂect
intrinsic resistance to treatment. The prognostic weight of mini-
mal residual disease assessed by ﬂow cytometry seems compara-
tively higher in the elders than in the young [27].
By contrast, the relative impact of molecular ﬁndings in the
elderly is poorly deﬁned, probably as a consequence of a less in-
tensive research in this population. At present time, the impact of
the associations appears to be in general the same than in the
young, despite the fact that their relative weight may be lower
[28]. Interestingly, in some particular cases, such as DNMT3A co-
don R882 mutations [29], the behavior is opposite.iﬁed.
eutic subset Therapeutic approach
iscussed within the
ic AML team
Clinical trial or Subset-directed AML therapy for adults
T candidate Clinical trial or Standard AML therapy for adults
able patients for toxicity
ICT/HCT
Clinical trial or
Alternative AML therapy for adults
/very ill patients Palliative care
y-case discussion Assign according to above criteria
ic assessment. ECOG¼Eastern Cooperative Oncology Group. HCT: Hemopoietic cell
L therapy for adults: the one that would receive a younger AML patient according to
tosine arabinoside, hypomethylating agents, etc.
Table 2
Prognostic features in elderly AML.
Study Rx Outcomes Prognosticators
ALFA Malfuson et al. Haematologica [60] ICT OS Poor risk cytogenetics or at least 2 other features (age474, PS41, WBC450.000)
MRC/LRF Wheatley et al. BJH [24] ICT OS Age, PS, WBC, cytogenetics, type of AML (de novo vs secondary)
MDACC Kantarjian et al. Blood [61] ICT ED Age (479), PS41, complex karyotype, creatinine41.3 mg/dL
AMLCG/SAL Krug et al. Lancet [62] ICT ED, CR, OS Age, body temperature, ﬁbrinogen, hemoglobin, platelet count, LDH, type of AML
(de novo vs secondary)
SAL Röllig et al. Blood [63] ICT OS, DFS Age, cytogenetics, WBC, LDH, CD34, NPM1
Elliot et al. Leuk Res [31] ICT ED, CR, OS Polypharmacy
Etienne et al. Cancer [30] ICT ED, CR, OS WBC, cytogenetics, CD34 (þ) blasts, CCI
Hulegardh et al. Am J Hematol [25] Any ED, CR, OS Secondary AML is not so important in elderly AML
Giles et al. BJH [34] ICT ED, OS HCT-CI
Klepin et al. Blood [16] ICT OS SPPBo9, 3MSo77
Deschler et al. Haematologica [32] ICT OS PS, IDL, HRQoL-item “fatigue”
Lazenby et al. Leukemia [28] ICT CR, OS NPM1, FLT3-ITD
Marcucci et al. JCO [29] ICT OS, DFS DNMT3A (R882)
Buccisano et al. Ann Oncol [27] ICT OS, CIR MRD, other
Khan et al. BJH [26] Any CR, OS CD34(þ) CD38(low) blasts
E-ALMA Ramos et al. Leuk Res [39] AZA CR, OS Real life conditions 100% Pts: 1st line Rx WBC (10.000) Cyto (abn) & PS [2]
Abn: Abnormal. AML: Acute myeloid leukemia. AZA: Azacitidine. CCI: Charlson comorbidity index. CIR: Cumulative incidence of relapse. CR: Complete remission. Cyto:
Cytogenetics. DFS: Disease-free survival. ECOG: Eastern Cooperative Oncology Group. ED: Early death (ﬁrst 4-8 weeks). HCT: Hemopoietic cell transplantation. HCT-CI:
Hemopoietic cell transplantation speciﬁc comorbidity index. HRQoL: Health-related quality-of-life. ICT: Intensive chemotherapy. MRD: Minimal residual disease. OS: Overall
survival. PS: Performance status. Rx: Therapy. SPPB: Short physical performance battery. 3MS: Modiﬁed mini-mental score.
Table 3
Main therapeutic drug comparisons in elderly AML.
Trial Rx Activity Obs.
EORTC Lowenberg, JCO [64] ICT vs. BCT n¼60 CR 58 vs. 0% Longer OS with ICT
(þ2.5 m), p¼0.015
BCT included HU/LDAC p.r.n. Median OS 21wk vs. 11wk Days
at hospital 55% vs 50%
Rouen Investigators Tilly, JCO [65] ICT vs. LDAC n¼87 CR 52 vs. 32% Similar OS, p¼NS ICT: more CRs, more ED, more infections, more transfusions,
more days at hospital
MRC AML14NI Burnett,
Cancer [66]
LDAC vs. BSC n¼212 CR 18 vs. 1% Longer OS with LDAC
OR 0.60, p¼0.009
29 pts with HR-MDS were included BSC included HU p.r.n.
No advantage in HR cyto (n¼42) Induction MRT 26 vs. 26% 1 yr OS
13% (whole series)
AZA-001 Fenaux, JCO [67] AZA vs. BCT n¼113, BMB 20–30% CR 18% vs.16%
Longer OS with AZA (þ9.5 m), p¼0.015
BCT included BSC, LDAC and ICT EMA and FDA approved
AML-001 Dombret, Blood [40] AZA vs. BCT n¼488, , BMB430% CR: 19.5 vs. 21.9%
Longer OS with AZA (þ5.2 m), p¼0.019
BCT included BSC, LDAC and ICT (n¼44). Exclusion: PS 42,
WBC 415.000, ﬁt for HSCT CR not needed for OS beneﬁt
Median OS: 12.1 vs. 6.9 m. 1y OS: 50.7 vs. 37.7% Same FN, ED and
HRQoL EMA: Filed; positive opinion FDA: not ﬁled to date
DACO16 Kantarjian, JCO [68] DAC vs. BCT n¼485 CRþCRp 17.8% Median OS: 8.5 m
Longer OS (þ2.7 m)
BCT included BSC or LDAC, not ICT Exclusion: PS42 Exclusion:
WBC440.000 EMA approved (430% BMB) FDA rejected 1y OS: 30%
AHD: Antecedent hematological disorder. AZA: Azacitidine. BCT: Best conventional therapy. BMB: Bone marrow blast proportion. BST: Best supportive therapy. CLO: Clo-
farabine. CR: Complete remission. CRp: Complete remission with incomplete platelet count recovery in peripheral blood. DAC: Decitabine. ED: Early death (ﬁrst 4-8 weeks).
FN: Febrile neutropenia. GO: Gemtuzumab-ozogamicin. HCT: Hemopoietic cell transplantation. HU: Hydroxyurea. HRQoL: Health-related quality-of-life. ICT: Intensive
chemotherapy. IDL: impairments in activities of daily living. LDAC: Low-dose cytosine arabinoside. PS: Performance status. OR: Odds-ratio. OS: Overall survival. Rx: Therapy
SAE: Severe adverse events.
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cohorts of patients participating in clinical trials, something that
might have hidden other patient-derived prognostic factors. In this
sense, comorbidity [5,30], polypharmacy [31], physical function
and cognition [32,33], as well as fatigue [32], appear to be also
relevant for prognosis, since they impact on patient's ability to
withstand the insult of chemotherapy and/or hematopoietic cell
transplantation (HCT). Among speciﬁc comorbidities, previous
cerebrovascular, renal, liver, psychiatric and rheumatological dis-
eases have been particularly associated with increased risk of
death [5]. As regards comorbidity scores, the Charlson comorbidity
index [17] and the HCT comorbidity index (HCT-CI) [34] have been
shown to predict overall survival in elderly AML.
4. Treatment options
Life expectancy in AML not only depends on the disease itself,but also on usual risk factors for mortality in the general popula-
tion. Nevertheless, the tremendous impact of AML on the short
term (conferring a very high relative mortality) overrides any other
consideration as regards the eventual need for speciﬁc therapy.
Thus, if the patient does not receive speciﬁc treatment, his/her life
expectancy will probably be only a few months since diagnosis,
although low-blast count AML might have a slower evolution [35].
Nowadays, only 40% of the elderly population receive speciﬁc AML
therapy within the ﬁrst 3 months from diagnosis in the US, ac-
cording to recent data from SEER-Medicare Database, highlighting
that there is much room for improvement in this ﬁeld [36].
Treatment options for elderly AML must be based on four main
factors: patient's clinical condition, disease characteristics, patient
wishes and social support. Thus, the most frail and oldest among
the oldest will have the least net beneﬁt from chemotherapy or
hematopoietic transplantation, even if they receive the best avail-
able treatment, while the ﬁttest and youngest patients will beneﬁt
Fig. 1. Overall survival by European ALMA Score. Full patient series. The tick marks
on the curves represent censored patients.
A.M. Almeida, F. Ramos / Leukemia Research Reports 6 (2016) 1–74most. Having said that, it is obvious that the “relative prognosis” of
an elderly AML patient will depend on our capability to administer
an effective treatment, and that the risk-beneﬁt of subjecting a
patient to intensive chemotherapy must be carefully weighed and
based not only on the predicted toxicity of the regimen, but also on
the likelihood of response, where cytogenetics play a dominant role.
Indeed, the relation between adverse cytogenetics and poor and
short-lived responses to intensive chemotherapy have been con-
sistently demonstrated [37,38]. The most favorable situation would
be a patient harboring acute promyelocytic leukemia, who can be
treated conventionally in most cases with rather optimistic ex-
pectations, followed by core-binding-factor leukemias, where the
beneﬁt of conventional chemotherapy is also important. In the re-
mainder of the elderly AML patients, intensive chemotherapy has
not consistently shown to improve overall survival within con-
trolled clinical trials (Table 3), and the information that supports its
potential beneﬁt comes from registry data. This is the consequence
not only of a high early mortality, but also of a short duration of the
responses [38]. Thus, the proportion of AML patients aged 65 years
and over that nowadays receive intensive chemotherapy in daily
practice is much lower than in the young [36]. The role of HCT in
the treatment of elderly AML will be discussed later on in this re-
view, but the proportion of older adults that are ﬁnally transplanted
is also small.
The comparisons of intensive vs. attenuated/supportive therapy
are scarce and of low quality. By contrast, higher-level evidence
supports the fact that patients treated with low-intensity regi-
mens live longer than those that received only supportive therapy
(Table 3). In practice, the physician should aim to proceed to
conventional intensive chemotherapy followed by hematopoietic
transplantation whenever this is feasible (taking into account
disease-related, patient-related and transplantation-related prog-
nostic factors), since this is the best option for curing the leukemia,
whereas supportive therapy alone should be avoided as much as
possible, and every effort should be made to administer at least
low-intensity chemotherapy. Recently, a predictive scoring system
for response and survival in elderly patients treated in real world
by azacitidine, based exclusively on clinical features, has been
developed and validated in Europe [39] (Table 4 and Fig. 1). Fur-
thermore, some data suggest that this drug might even result in
superior OS, as compared to intensive chemotherapy or low-dose
cytarabine, in patients harboring high-risk cytogenetics, MDS-re-
lated AML, or erythroleukemia [40–42]. This might be improved in
the near future by including some molecular predictors such asTable 4
European ALMA score.
European ALMA score
Applicability Unﬁt WHO-deﬁned AML patients (any blast count)







WBC count before AZA
onset
Up to 10109/L 0
Greater than 10109/L 1
Cytogenetics Normal 0
Abnormal 1






AML¼Acute myeloid leukemia. ECOG: Eastern Cooperative Oncology Group. WBC:
White blood cell. OS: Overall survival. AZA: Azacitidine. ALMA stands for “Azaciti-
dina en el tratamiento de la leucemia aguda mieloblástica” (AZA in AML therapy).mutations in TET2 [43] and IDH1/2 [44].
Despite promising response rates, none of the various other
agents tested, other than azacitidine in low-blast count leukemia,
have been able to overcome the 12 months landmark for median
overall survival (Table 5) and there is great need for novel agents
in this group of patients.
Currently, there are numerous novel agents being tested in
clinical trials, many of which target recently described molecular
defects. These include modiﬁed cytotoxics, epigenetic regulators,
cell cycle kinase inhibitors, etc. Many are currently being tested in
monotherapy or in combination with already established regi-
mens. According to very preliminary results from Phase I/II trials,
several agents hold promise, such as a) The FLT3 inhibitors gil-
teritinib (ASP2215) [45] and sorafenib [46], which have been tes-
ted in monotherapy, and in combination with chemotherapy in theTable 5
Therapeutic efﬁcacy (complete response rate and median overall survival) of dif-
ferent drugs used for elderly patients with AML.
Regimen CR rate (%) Median OS (months)
Intensive chemotherapy [64,65] 50–60 6–12
LDAC [65,66] 10–25 6
Azacitidine in low-blast count AM [67] 25 24.5
Azacitidine in AML430% BMB [40] 25 12.1
Decitabine in AML430% BMB [68] 18 7.7
Clofarabine [69] 38 11.4
Sapacitabine [70] 37 7.9
Barasertib [71] 35 8.2
Volasertib (þ LDAC) [72] 31 8
Tipifarnib [73] 8 3.6
Midostaurin (þAZA) [74] 2 NA
Quizartinib [75] 54 o12
Vorinostat (þLDAC) [76] 46 NA
Gemtuzumab ozogamicin [77] 30 11
CR: Complete remission. LDAC: Low dose cytarabine. BMB: Bone marrow blasts. OS:
Overall survival. NA: Not available.
Table 6
HCT according to patient and AML considerations.
HCT-CI score [18] EBMT score [57] NRM at 4 years
0 0–3 11%
0 Greater than 3 19%
1–2 0–3 16%
1–2 Greater than 3 28%
Greater than 2 0–3 31%
Greater than 2 Greater than 2 41%
EBMT: European group for blood and marrow transplantation. HCT-CI: Hemo-
poietic cell transplantation speciﬁc comorbidity index. NRM: Non-relapse
mortality.
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as high as 50% in patients with FLT3 mutations. Combination of
sorafenib with chemotherapy in adults with mutated FLT3 im-
proved 1 yr survival from 30% to 62% [46]. As regards the multi-
kinase inhibitor midostaurin, its efﬁcacy in combination with
standard chemotherapy (RATIFY trial) in patients under 60 [47] is
yet to be proved in patients over 60, b) The Inhibitors of IDH1 and
IDH2, which have obtained overall response rates of about 40% in
heavily pre-treated older AML patients harboring IDH-1 or IDH-2
mutations [48], c) The addition of the HDAC inhibitor pracinostat
to azacitidine, that achieved 1-year survival rates of 60% with 54%
overall response rate [49], d) Monoclonal antibodies, such as va-
dastuximab talirine (SGN-CD33A), an anti-CD33 antibody con-
jugated with a pyrrolobenzodiazepine dimer, as well as Durvalu-
mab, an anti-PD-L1 antibody, that have shown promising pre-
liminary response rates and are currently being tested further
[50,51].
The progressive unraveling of the molecular pathophysiology of
AML is likely to identify more therapeutic targets, which may
widen in the near future the therapeutic armamentarium for el-
derly AML.5. Hematopoietic cell transplantation
HCT is generally recommended for AML patients with inter-
mediate or high risk cytogenetics, when the aim of treatment is
curative. However, elderly patients are seldom offered a transplant
mainly due to concerns regarding toxicity, despite the fact that the
main reason for death after HCT in the older adult is not toxicity
but relapse [52]. Fortunately, there has been a steady increase in
the number of HCTs in this patient group in the past decade [53] as
a consequence of the introduction of less intensive conditioning
regimes, which have signiﬁcantly reduced toxicity whilst main-
taining successful engraftment. Nevertheless, nowadays only
about 8% of elderly patients with AML undergo HCT each year in
the US [36], even though they constitute more than 50% of the
new AML cases.
Outcome analysis in this population indicates that those who
are submitted to HCT have a relatively favorable outcome, with
almost 40% 3-year relapse-free and overall survival [54]. It is
therefore essential to identify those patients whose ﬁtness and
disease characteristics make them the best candidates for trans-
plant. Beyond chronological age [55], factors that predict OS and
relapse are high risk AML (cytogenetics, gene mutations), higher
HCT-CI scores, patient CMV status and greater HLA disparity, while
the impact of donor age is still disputed, especially in the context
of reduced-intensity conditioning regimes. In addition, poor per-
formance status and active infections are associated with poorer
outcomes and these patients should not be transplanted, unless
their condition improves. Similarly, patients who have active dis-
ease at the time of HCT are very unlikely to maintain remission
long term, and should be rather rescued with chemotherapy and
transplanted when in CR. Patients with favorable prognostic dis-
ease, especially those with CBF mutations and no additional poor
risk cytogenetic or molecular markers, do well with consolidation
chemotherapy and do not beneﬁt from transplant in ﬁrst remis-
sion. Therefore all elderly patients with good performance status
(ECOG PS 0-1) and with any disease risk other than the good
prognostic group should be considered for HCT, depending on
their HCT-CI [56] and EBMT [57] risk score (Table 6).
The role of geriatric assessment in identifying patient vulner-
abilities before HCT is still in the beginning, but gait speed, in-
strumental activities of daily living and cognition evaluation,
among other clinical parameters, seem to be useful for this pur-
pose [58]. The analysis of the impact of HCT on the quality-of-lifeof the older adults is also very much in its infancy. Lastly, it should
be emphasized that HCT candidates must be identiﬁed at diagnosis
and this option discussed upfront with the patient as some elderly
patients may not agree on an aggressive treatment course.6. Social issues
Dependency, disability, general functioning, cognition, quality-
of-life, caregiver, burden of disease…are recurrent terms when
confronting diseases of the elderly. Many older adults, but not
most, would keep free of dependency and disability until late in
their lives, and the very proportion will depend on their previous
life-style and comorbidity. In this population, the optimal target
should be to cure the disease without compromising heavily the
quality-of-life on the short term, as well maintaining general
functioning and cognition on the long term. A systematic evalua-
tion of quality-of-life during treatment and general functioning
and cognition of this population, before and after treatment,
would be of great help for informing clinical decisions, but for the
time being the available information is scarce.
Social and family support is critical in patients dependent for
basic activities of daily life, but also for those dependent only for
instrumental activities or even in the independent ones (limited
budget, frequent hospital visits, unexpected medical complica-
tions, less prone to visit the Emergency Department) [59]. Such a
support may modulate the type and intensity of the treatment to
be given, even in the best developed countries, and becomes cri-
tical when welfare state is less than optimal.
Finally, the burden of disease in elderly AML is huge, for the
patient, his/her family and the whole society, and specially in this
time of targeted therapy. It is the physician's responsibility to try
and make an optimal use of scarce resources to achieve the best
outcomes while avoiding discrimination purely on grounds of age.7. Conclusion
Treatment options remain limited for older adults with AML. It
is essential to tailor the choice of therapy to patient's condition
and disease characteristics, and a few patients beneﬁt from ag-
gressive approaches. Some novel agents hold promise, but it is
unlikely that they will achieve much beneﬁt as single agents and,
hopefully, combinations may provide better results in the future.
HCT is increasingly safer and, therefore, more feasible in this pa-
tient population but the toxicities of previous treatments and the
logistics of donor availability may delay the transplant and put at
risk the fragile remissions which may have been obtained. Whe-
ther as a bridge to transplant or on their own, low-intensity ap-
proaches may help to improve the outlook of elderly patients with
AML.
A.M. Almeida, F. Ramos / Leukemia Research Reports 6 (2016) 1–76Finally, additional research on the impact of pre-treatment
geriatric assessment and different therapeutic approaches, in-
cluding HCT, on the quality-of-life of older adults, as well as higher
social awareness of the huge resources concerned to improve the
outcome of this elderly population in the near future, is much
needed.Disclosures
AA is a consultant for Celgene and Novartis and serves on the
speakers bureau of Bristol-Meyers Squibb, Alexion, Shire and
Amgen.
FR has received honoraria from Celgene, Janssen-Cilag, Amgen,
Novartis, Merck-Sharp & Dohme, Pﬁzer, Roche and GlaxoSmithK-
line; research grants from Celgene; has been Consultant for Amgen
and Novartis and served as member of Advisory Boards of Celgene
and Janssen-Cilag.References
[1] Cancer Statistics Review 1975–2003: I Table–11median age of cancer patients
at diagnosis, 2000–2003 by primary cancersite, race and sex. [database on the
Internet]. National Cancer Institute. (cited 01.02.16), 2003.
[2] S.M. Alibhai, M. Leach, M.D. Minden, J. Brandwein, Outcomes and quality of
care in acute myeloid leukemia over 40 years, Cancer 115 (13) (2009)
2903–2911.
[3] J. Menzin, K. Lang, C.C. Earle, D. Kerney, R. Mallick, The outcomes and costs of
acute myeloid leukemia among the elderly, Arch. Intern Med. 162 (14) (2002)
1597–1603.
[4] Global Health Observatory Data (database on the Internet). WHO. (cited
01.02.16), 2016. Available from: 〈http://www.who.int/gho/mortality_burden_
disease/life_tables/life_tables/en/〉.
[5] M. Mohammadi, Y. Cao, I. Glimelius, M. Bottai, S. Eloranta, K.E. Smedby, The
impact of comorbid disease history on all-cause and cancer-speciﬁc mortality
in myeloid leukemia and myeloma – a Swedish population-based study, BMC
Cancer 15 (2015) 850.
[6] C.P. Leith, K.J. Kopecky, J. Godwin, T. McConnell, M.L. Slovak, I.M. Chen, et al.,
Acute myeloid leukemia in the elderly: assessment of multidrug resistance
(MDR1) and cytogenetics distinguishes biologic subgroups with remarkably
distinct responses to standard chemotherapy. A Southwest Oncology Group
study, Blood 89 (9) (1997) 3323–3329.
[7] J.P. Patel, M. Gonen, M.E. Figueroa, H. Fernandez, Z. Sun, J. Racevskis, et al.,
Prognostic relevance of integrated genetic proﬁling in acute myeloid leukemia,
New Engl. J. Med. 366 (12) (2012) 1079–1089.
[8] A.V. Rao, P.J. Valk, K.H. Metzeler, C.R. Acharya, S.A. Tuchman, M.M. Stevenson,
et al., Age-speciﬁc differences in oncogenic pathway dysregulation and an-
thracycline sensitivity in patients with acute myeloid leukemia, J. Clin. Oncol.
27 (33) (2009) 5580–5586.
[9] M.E. Figueroa, L. Skrabanek, Y. Li, A. Jiemjit, T.E. Fandy, E. Paietta, et al., MDS
and secondary AML display unique patterns and abundance of aberrant DNA
methylation, Blood 114 (16) (2009) 3448–3458.
[10] NCCN, National comprehensive cancer network, NCCN clinical practice
guidelines in oncology, Older adult oncology. Version 2.2015. Retrieved from
〈http://www.nccn.org/professionals/ physician_gls/PDF/senior.pdf〉. (Accesed
09.01.16), 2016.
[11] D. Saliba, M. Elliott, L.Z. Rubenstein, D.H. Solomon, R.T. Young, C.J. Kamberg,
et al., The vulnerable elders survey: a tool for identifying vulnerable older
people in the community, J. Am. Geriatr. Soc. 49 (12) (2001) 1691–1699.
[12] M.E. Hamaker, M. Mitrovic, R. Stauder, The G8 screening tool detects relevant
geriatric impairments and predicts survival in elderly patients with a hae-
matological malignancy, Ann. Hematol. 93 (6) (2014) 1031–1040.
[13] M.E. Hamaker, M.C. Prins, R. Stauder, The relevance of a geriatric assessment
for elderly patients with a haematological malignancy–a systematic review,
Leuk. Res. 38 (3) (2014) 275–283.
[14] M.E. Hamaker, A.H. Schiphorst, D. ten Bokkel Huinink, C. Schaar, B.C. van
Munster, The effect of a geriatric evaluation on treatment decisions for older
cancer patients–a systematic review, Acta Oncol. 53 (3) (2014) 289–296.
[15] H.D. Klepin, Geriatric perspective: how to assess ﬁtness for chemotherapy in
acute myeloid leukemia, Hematol. Am. Soc. Hematol. Educ. Program 2014 (1)
(2014) 8–13.
[16] H.D. Klepin, A.M. Geiger, J.A. Tooze, S.B. Kritchevsky, J.D. Williamson, T.
S. Pardee, et al., Geriatric assessment predicts survival for older adults re-
ceiving induction chemotherapy for acute myelogenous leukemia, Blood 121
(21) (2013) 4287–4294.
[17] M.E. Charlson, P. Pompei, K.L. Ales, C.R. MacKenzie, A new method of classi-
fying prognostic comorbidity in longitudinal studies: development andBM,
Maloney DG, et al. Hematopoietic cell transplantation (HCT)-speciﬁccomorbidity index: a new tool for risk assessment before allogeneic HCT,
Blood 106 (8) (2005) 2912–2919.
[18] M.L. Sorror, M.B. Maris, R. Storb, F. Baron, B.M. Sandmaier, D.G. Maloney, et al.,
Hematopoietic cell transplantation (HCT)-speciﬁc comorbidity index: a new
tool for risk assessment before allogeneic HCT, Blood 106 (8) (2005)
2912–2919.
[19] J.M. Guralnik, E.M. Simonsick, L. Ferrucci, R.J. Glynn, L.F. Berkman, D.G. Blazer,
et al., A short physical performance battery assessing lower extremity func-
tion: association with self-reported disability and prediction of mortality and
nursing home admission, J. Gerontol. 49 (2) (1994) M85–M94.
[20] J.M. Guralnik, L. Ferrucci, E.M. Simonsick, M.E. Salive, R.B. Wallace, Lower-
extremity function in persons over the age of 70 years as a predictor of sub-
sequent disability, New Engl. J. Med. 332 (9) (1995) 556–561.
[21] S. Studenski, S. Perera, K. Patel, C. Rosano, K. Faulkner, M. Inzitari, et al., Gait
speed and survival in older adults, JAMA 305 (1) (2011) 50–58.
[22] E.L. Teng, H.C. Chui, The modiﬁed mini-mental state (3MS) examination, J.
Clin. Psychiatry 48 (8) (1987) 314–318.
[23] E. Pfeiffer, A short portable mental status questionnaire for the assessment of
organic brain deﬁcit in elderly patients, J. Am. Geriatr. Soc. 23 (10) (1975)
433–441.
[24] K. Wheatley, C.L. Brookes, A.J. Howman, A.H. Goldstone, D.W. Milligan, A.
G. Prentice, et al., Prognostic factor analysis of the survival of elderly patients
with AML in the MRC AML11 and LRF AML14 trials, Br. J. Haematol. 145 (5)
(2009) 598–605.
[25] E. Hulegardh, C. Nilsson, V. Lazarevic, H. Garelius, P. Antunovic, A. Rangert
Derolf, et al., Characterization and prognostic features of secondary acute
myeloid leukemia in a population-based setting: a report from the Swedish
Acute Leukemia Registry, Am. J. Hematol. 90 (3) (2015) 208–214.
[26] N. Khan, S.D. Freeman, P. Virgo, S. Couzens, P. Richardson, I. Thomas, et al., An
immunophenotypic pre-treatment predictor for poor response to induction
chemotherapy in older acute myeloid leukaemia patients: blood frequency of
CD34þCD38 low blasts, Br. J. Haematol. 170 (1) (2015) 80–84.
[27] F. Buccisano, L. Maurillo, A. Piciocchi, M.I. Del Principe, C. Sarlo, M. Cefalo,
et al., Minimal residual disease negativity in elderly patients with acute
myeloid leukemia may indicate different postremission strategies than in
younger patients, Ann. Hematol. 94 (8) (2015) 1319–1326.
[28] M. Lazenby, A.F. Gilkes, C. Marrin, A. Evans, R.K. Hills, A.K. Burnett, The
prognostic relevance of ﬂt3 and npm1 mutations on older patients treated
intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16
trial, Leukemia 28 (10) (2014) 1953–1959.
[29] G. Marcucci, K.H. Metzeler, S. Schwind, H. Becker, K. Maharry, K. Mrozek, et al.,
Age-related prognostic impact of different types of DNMT3A mutations in
adults with primary cytogenetically normal acute myeloid leukemia, J. Clin.
Oncol. 30 (7) (2012) 742–750.
[30] A. Etienne, B. Esterni, A. Charbonnier, M.J. Mozziconacci, C. Arnoulet, D. Coso,
et al., Comorbidity is an independent predictor of complete remission in el-
derly patients receiving induction chemotherapy for acute myeloid leukemia,
Cancer 109 (7) (2007) 1376–1383.
[31] K. Elliot, J.A. Tooze, R. Geller, B.L. Powell, T.S. Pardee, E. Ritchie, et al., The
prognostic importance of polypharmacy in older adults treated for acute
myelogenous leukemia (AML), Leuk. Res. 38 (10) (2014) 1184–1190.
[32] B. Deschler, G. Ihorst, U. Platzbecker, U. Germing, E. Marz, M. de Figuerido,
et al., Parameters detected by geriatric and quality of life assessment in 195
older patients with myelodysplastic syndromes and acute myeloid leukemia
are highly predictive for outcome, Haematologica 98 (2) (2013) 208–216.
[33] H.D. Klepin, Predicting treatment outcomes in older patients with acute
myelogenous leukemia, Clin. Adv. Hematol. Oncol. 11 (10) (2013) 669–671.
[34] F.J. Giles, G. Borthakur, F. Ravandi, S. Faderl, S. Verstovsek, D. Thomas, et al.,
The haematopoietic cell transplantation comorbidity index score is predictive
of early death and survival in patients over 60 years of age receiving induction
therapy for acute myeloid leukaemia, Br. J. Haematol. 136 (4) (2007) 624–627.
[35] R.P. Hasserjian, F. Campigotto, V. Klepeis, B. Fu, S.A. Wang, C. Bueso-Ramos,
et al., De novo acute myeloid leukemia with 20–29% blasts is less aggressive
than acute myeloid leukemia with 4/¼30% blasts in older adults: a Bone
Marrow Pathology Group study, Am. J. Hematol. 89 (11) (2014), E193-9.
[36] B.C. Medeiros, S. Satram-Hoang, D. Hurst, K.Q. Hoang, F. Momin, C. Reyes, Big
data analysis of treatment patterns and outcomes among elderly acute mye-
loid leukemia patients in the United States, Ann. Hematol. 94 (7) (2015)
1127–1138.
[37] D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C.J. Harrison, et al.,
The predictive value of hierarchical cytogenetic classiﬁcation in older adults
with acute myeloid leukemia (AML): analysis of 1065 patients entered into the
United Kingdom Medical Research Council AML11 trial, Blood 98 (5) (2001)
1312–1320.
[38] H. Kantarjian, S. O’Brien, J. Cortes, F. Giles, S. Faderl, E. Jabbour, et al., Results of
intensive chemotherapy in 998 patients age 65 years or older with acute
myeloid leukemia or high-risk myelodysplastic syndrome: predictive prog-
nostic models for outcome, Cancer 106 (5) (2006) 1090–1098.
[39] F. Ramos, S. Thepot, L. Pleyer, L. Maurillo, R. Itzykson, J. Bargay, et al., Azaci-
tidine frontline therapy for unﬁt acute myeloid leukemia patients: clinical use
and outcome prediction, Leuk. Res. 39 (3) (2015) 296–306.
[40] H. Dombret, J.F. Seymour, A. Butrym, A. Wierzbowska, D. Selleslag, J.H. Jang,
et al., International phase 3 study of azacitidine vs conventional care regimens
in older patients with newly diagnosed AML with 430% blasts, Blood 126 (3)
(2015) 291–299.
[41] J.T.S. Falantes, L. Pleyer, L. Maurillo, V. Martínez-Robles, R. Itzykson, J. Bargay,
A.M. Almeida, F. Ramos / Leukemia Research Reports 6 (2016) 1–7 7R. Stauder, A. Venditti, M.P. Martínez, R. Seegers, M.A. Foncillas, S. Burgstaller,
C. Gardin, P. Montesinos, P. Musto, R. Greil, M.A. Sanz, P. Fenaux, F. Ramos, For
the European ALMA Investigators, Azacitidine in older patients with acute
myeloid leukemia (AML), Results from the expanded international E-ALMA
series (E-ALMAþ) according to the MRC risk index score, in: Proceedings of
the Annual Conference of the American Society for Hematology, 2015, pp.
2554.
[42] F. Pierdomenico, S. Esteves, A. Almeida, Efﬁcacy and tolerability of 5-day
azacytidine dose-intensiﬁed regimen in higher-risk MDS, Ann. Hematol. 92 (9)
(2013) 1201–1206.
[43] R. Itzykson, O. Kosmider, T. Cluzeau, V. Mansat-De Mas, F. Dreyfus, O. Beyne-
Rauzy, et al., Impact of TET2 mutations on response rate to azacitidine in
myelodysplastic syndromes and low blast count acute myeloid leukemias,
Leukemia 25 (7) (2011) 1147–1152.
[44] A. Emadi, R. Faramand, B. Carter-Cooper, S. Tolu, L.A. Ford, R.G. Lapidus, et al.,
Presence of isocitrate dehydrogenase mutations may predict clinical response
to hypomethylating agents in patients with acute myeloid leukemia, Am. J.
Hematol. 90 (5) (2015) E77–E79.
[45] C. Thom, Preliminary data on ASP2215: tolerability and efﬁcacy in acute
myeloid leukemia patients, Future Oncol. 11 (18) (2015) 2499–2501.
[46] 1 C. Röllig, H. Serve, A. Hüttmann, R. Noppeney, C. Müller-Tidow, U. Krug,
et al., Study Alliance Leukaemia. Addition of sorafenib versus placebo to
standard therapy in patients aged 60 years or younger with newly diagnosed
acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised
controlled trial, Lancet Oncol. 16 (16) (2015) 1691–1699.
[47] R.M. Stone, S. Mandrekar, B.L. Sanford, S. Geyer, C.D. Bloomﬁeld, K. Dohner,
et al., The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared
with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine
(C) Induction (in)d), High-Dose C Consolidation (consol), (and As Maintenance
(main)t) (Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Pa-
tients (pt)s) (Age 18-60 with FLT3 Mutations (mut)s): (An International Pro-
spective Randomized (ran)d) (P-Controlled Double-Blind Trial (CALGB 10603/
RATIFY [Allianc)e]), Blood 126 (23) (2015) 6-6.
[48] E.M. Stein, IDH2 inhibition in AML: ﬁnally progress? Best Pract. Res. Clin.
Haematol. 28 (2–3) (2015) 112–115.
[49] G. Garcia-Manero, E. Atallah, S.K. Khaled, M. Arellano, M.M. Patnaik, T. Butler,
et al., Final Results from a Phase 2 Study of Pracinostat in Combination with
Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML), Blood 126
(23) (2015) 453.
[50] A.T. Fathi, H. Erba, J. Lancet, E.M. Stein, R. Walter, D.J. De Angelo, et al., SGN-
CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with
High Remission Rate in Frontline Unﬁt AML, Blood 126 (23) (2015) 454.
[51] A. Fandi, D.M. Reiser, D. Barton, D. Begic, Methods for treating a disease or
disorder using oral formulations of cytidine analogs in combination with an
Anti-PD2 or Anti-PDL1 monoclonal antibody, 2016. Available from: 〈http://
www.freepatentsonline.com/y2016/0067336.html〉.
[52] J. Aoki, H. Kanamori, M. Tanaka, S. Yamasaki, T. Fukuda, H. Ogawa, et al., Im-
pact of age on outcomes of allogeneic hematopoietic stem cell transplantation
with reduced intensity conditioning in elderly patients with acute myeloid
leukemia, Am. J. Hematol. 91 (3) (2016) 302–307.
[53] S. Sengsayadeth, B.N. Savani, D. Blaise, F. Malard, A. Nagler, M. Mohty, Reduced
intensity conditioning allogeneic hematopoietic cell transplantation for adult
acute myeloid leukemia in complete remission – a review from the Acute
Leukemia Working Party of the EBMT, Haematologica 100 (7) (2015) 859–869.
[54] J. Aoki, H. Kanamori, M. Tanaka, S. Yamasaki, T. Fukuda, H. Ogawa, et al., Im-
pact of age on outcomes of allogeneic hematopoietic stem cell transplantation
with reduced intensity conditioning in elderly patients with acute myeloid
leukemia, Am. J. Hematol. 91 (3) (2016) 302–307.
[55] M.L. Sorror, R.F. Storb, B.M. Sandmaier, R.T. Maziarz, M.A. Pulsipher, M.
B. Maris, et al., Comorbidity-age index: a clinical measure of biologic age be-
fore allogeneic hematopoietic cell transplantation, J. Clin. Oncol. 32 (29)
(2014) 3249–3256.
[56] M.L. Sorror, E. Estey, Allogeneic hematopoietic cell transplantation for acute
myeloid leukemia in older adults, Hematol. Am. Soc. Hematol. Educ. Program.
2014 (1) (2014) 21–33.
[57] F.V. Michelis, H.A. Messner, J. Uhm, N. Alam, A. Lambie, L. McGillis, et al.,
Modiﬁed EBMT pretransplant risk score can identify favorable-risk patients
undergoing allogeneic hematopoietic cell transplantation for AML, not Iden-
tiﬁed by the HCT-CI score, Clin. Lymphoma Myeloma Leuk. 15 (5) (2015)
e73–e81.
[58] L.S. Mufﬂy, M. Kocherginsky, W. Stock, Q. Chu, M.R. Bishop, L.A. Godley, et al.,
Geriatric assessment to predict survival in older allogeneic hematopoietic cell
transplantation recipients, Haematologica 99 (8) (2014) 1373–1379.
[59] A.L. Bryant, A.M. Deal, A. Walton, W.A. Wood, H. Muss, D.K. Mayer, Use of ED
and hospital services for patients with acute leukemia after induction therapy:
one year follow-up, Leuk. Res. 39 (4) (2015) 406–410.[60] J.V. Malfuson, A. Etienne, P. Turlure, T. de Revel, X. Thomas, N. Contentin, et al.,
Risk factors and decision criteria for intensive chemotherapy in older patients
with acute myeloid leukemia, Haematologica 93 (12) (2008) 1806–1813.
[61] H. Kantarjian, F. Ravandi, S. O’Brien, J. Cortes, S. Faderl, G. Garcia-Manero, et al.,
Intensive chemotherapy does not beneﬁt most older patients (age 70 years or
older) with acute myeloid leukemia, Blood 116 (22) (2010) 4422–4429.
[62] U. Krug, C. Rollig, A. Koschmieder, A. Heinecke, M.C. Sauerland, M. Schaich,
et al., Complete remission and early death after intensive chemotherapy in
patients aged 60 years or older with acute myeloid leukaemia: a web-based
application for prediction of outcomes, Lancet 376 (9757) (2010) 2000–2008.
[63] C. Rollig, C. Thiede, M. Gramatzki, W. Aulitzky, H. Bodenstein, M. Bornhauser,
et al., A novel prognostic model in elderly patients with acute myeloid leu-
kemia: results of 909 patients entered into the prospective AML96 trial, Blood
116 (6) (2010) 971–978.
[64] B. Lowenberg, R. Zittoun, H. Kerkhofs, U. Jehn, J. Abels, L. Debusscher, et al., On
the value of intensive remission-induction chemotherapy in elderly patients
of 65þ years with acute myeloid leukemia: a randomized phase III study of
the European Organization for Research and Treatment of Cancer Leukemia
Group, J. Clin. Oncol. 7 (9) (1989) 1268–1274.
[65] H. Tilly, S. Castaigne, D. Bordessoule, P. Casassus, P.Y. Le Prise, G. Tertian, et al.,
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute
nonlymphocytic leukemia in the elderly, J. Clin. Oncol. 8 (2) (1990) 272–279.
[66] A.K. Burnett, D. Milligan, A.G. Prentice, A.H. Goldstone, M.F. McMullin, R.
K. Hills, et al., A comparison of low-dose cytarabine and hydroxyurea with or
without all-trans retinoic acid for acute myeloid leukemia and high-risk
myelodysplastic syndrome in patients not considered ﬁt for intensive treat-
ment, Cancer 109 (6) (2007) 1114–1124.
[67] P. Fenaux, G.J. Mufti, E. Hellstrom-Lindberg, V. Santini, N. Gattermann,
U. Germing, et al., Azacitidine prolongs overall survival compared with con-
ventional care regimens in elderly patients with low bone marrow blast count
acute myeloid leukemia, J. Clin. Oncol. 28 (4) (2010) 562–569.
[68] H.M. Kantarjian, X.G. Thomas, A. Dmoszynska, A. Wierzbowska, G. Mazur,
J. Mayer, et al., Multicenter, randomized, open-label, phase III trial of decita-
bine versus patient choice, with physician advice, of either supportive care or
low-dose cytarabine for the treatment of older patients with newly diagnosed
acute myeloid leukemia, J. Clin. Oncol. 30 (21) (2012) 2670–2677.
[69] A.K. Burnett, N.H. Russell, A.E. Hunter, D. Milligan, S. Knapper, K. Wheatley,
et al., Clofarabine doubles the response rate in older patients with acute
myeloid leukemia but does not improve survival, Blood 122 (8) (2013)
1384–1394.
[70] A.K. Burnett, N. Russell, R.K. Hills, N. Panoskaltsis, A. Khwaja, C. Hemmaway,
et al., A randomised comparison of the novel nucleoside analogue sapacita-
bine with low-dose cytarabine in older patients with acute myeloid leukae-
mia, Leukemia 29 (6) (2015) 1312–1319.
[71] H.M. Kantarjian, G. Martinelli, E.J. Jabbour, A. Quintas-Cardama, K. Ando, J.
O. Bay, et al., Stage I of a phase 2 study assessing the efﬁcacy, safety, and
tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in
elderly patients with acute myeloid leukemia, Cancer 119 (14) (2013)
2611–2619.
[72] H. Dohner, M. Lubbert, W. Fiedler, L. Fouillard, A. Haaland, J.M. Brandwein,
et al., Randomized, phase 2 trial of low-dose cytarabine with or without vo-
lasertib in AML patients not suitable for induction therapy, Blood 124 (9)
(2014) 1426–1433.
[73] J.L. Harousseau, G. Martinelli, W.W. Jedrzejczak, J.M. Brandwein,
D. Bordessoule, T. Masszi, et al., A randomized phase 3 study of tipifarnib
compared with best supportive care, including hydroxyurea, in the treatment
of newly diagnosed acute myeloid leukemia in patients 70 years or older,
Blood 114 (6) (2009) 1166–1173.
[74] P. Strati, H. Kantarjian, F. Ravandi, A. Nazha, G. Borthakur, N. Daver, et al., Phase
I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for
patients with acute myeloid leukemia and myelodysplastic syndrome, Am. J.
Hematol. 90 (4) (2015) 276–281.
[75] J.E. Cortes, H. Kantarjian, J.M. Foran, D. Ghirdaladze, M. Zodelava, G. Borthakur,
et al., Phase I study of quizartinib administered daily to patients with relapsed
or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase
3-internal tandem duplication status, J. Clin. Oncol. 31 (29) (2013) 3681–3687.
[76] T. Prebet, T. Braun, O. Beyne-Rauzy, F. Dreyfus, A. Stammatoullas, E. Wattel,
et al., Combination of vorinostat and low dose cytarabine for patients with
azacitidine-refractory/relapsed high risk myelodysplastic syndromes, Leuk.
Res. 38 (1) (2014) 29–33.
[77] S. Amadori, S. Suciu, D. Selleslag, F. Aversa, G. Gaidano, M. Musso, et al.,
Gemtuzumab ozogamicin versus best supportive care in older patients with
newly diagnosed acute myeloid leukemia unsuitable for intensive che-
motherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial,
J. Clin. Oncol. 34 (9) (2016) 972–979.
